恩替卡韦治疗慢性乙型病毒性肝炎患者的临床研究  

Clinical trial of entecavir in the treatment of patients with chronic hepatitis B

作　　者：张丽翠[1] 钟晨[2] 张砚[3] 黄川生[4] 曹文疆[1] 马雅静[1] ZHANG Li-cui;ZHONG Chen;ZHANG Yan;HUANG Chuan-sheng;CAO Wen-jiang;MA Ya-jing(Department of Laboratory,First Affiliated Hospital of Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China;Department of Third General Surgery,First Affiliated Hospital of Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China;Department of Infection,First Affiliated Hospital of Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China;Department of Pharmaceutical,First Affiliated Hospital of Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]石河子大学医学院第一附属医院检验科,新疆石河子832000 [2]石河子大学医学院第一附属医院普外三科,新疆石河子832000 [3]石河子大学医学院第一附属医院感染科,新疆石河子832000 [4]石河子大学医学院第一附属医院药剂科,新疆石河子832000

出　　处：《中国临床药理学杂志》2019年第20期2539-2542,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的 观察恩替卡韦对慢性乙型病毒性肝炎(乙肝,CHB)患者肝功能、乙肝病毒载量(HBV-DNA)及肝纤维化的影响。方法 入选我院感染科就诊的118例CHB患者,随机分为对照组和试验组,各59例。所有患者均给予常规护肝治疗,对照组在常规治疗的基础上给予阿德福韦酯10 mg,每天1次,口服;试验组在常规治疗的基础上给予恩替卡韦片0. 5 mg,每天1次,口服,连续治疗48周,治疗后观察1年。比较2组患者治疗前后肝功能、HBV-DNA、T细胞亚群、炎症因子及肝纤维化指标水平。结果 治疗后,对照组与试验组血清谷丙转氨酶(GPT)水平分别为(43. 39±9. 18),(39. 64±8. 34) U·L^-1;谷草转氨酶(GOT)水平分别为(45. 62±10. 25),(37. 28±9. 06) U·L^-1;HBV-DNA含量分别为(3. 29±1. 25),(2. 77±1. 04) Log10拷贝/毫升,差异均有统计学意义(均P <0. 05)。2组药物不良反应发生率差异无统计学意义(P> 0. 05)。结论 恩替卡韦可显著改善CHB患者的肝功能,通过抑制HBV复制,减轻肝炎症反应。Objective To investigate the effects of entecavir on liver function,hepatitis B virus load(HBV-DNA)and liver fibrosis in patients with chronic hepatitis B(CHB).Methods One hundred and eighteen CHB patients were randomly divided into control group and treatment group,with 59 patients in each group.All patients were given conventional liver protection treatment,while control group was given adefovir dipivoxil tablets 10 mg,1 time per day,oral;treatment group was given entecavir tablets 0.5 mg,1 time per day,oral.Both groups were treated for 48 weeks and observed for 1 year.The liver function,HBV-DNA,T cell subsets,inflammatory factors and liver fibrosis indexes were observed and compared between the two groups.Results After treatment,the serum glutamic-pyruvic transaminase(GPT)in control group and treatment group were(43.39±9.18),(39.64±8.34)U·L^-1;serum glutamic-oxaloacetic transaminase(GOT)were(45.62±10.25),(37.28±9.06)U·L^-1;the HBV-DNA were(3.29±1.25),(2.77±1.04)Log10 copies·m L^-1,all with significant difference(all P<0.05).There was no significnat difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Entecavir can significantly improve the liver function of patients with CHB by inhibiting HBV replication,alleviating hepatic inflammation and preventing further development of liver fibrosis.

关 键 词：恩替卡韦 慢性乙型病毒性肝炎 肝功能 肝纤维化 免疫 

分 类 号：R978.7[医药卫生—药品]